There are suprisingly few data or statistics on the costs of cancer or cancer chemotherapy. There is also considerable misunderstanding about the economics of cancer treatment, and much of this misunderstanding seems to arise from the very high costs of some individual treatments. In some cases these may be as much as £150 for a single dose. This paper attempts to gather and present what statistics are available. It also discusses some of the reasons behind the current misconceptions about the cost and economics of cancer chemotherapy.
One important source of statistics is a chapter on the 'Economic Costs of Cancer' (Hodgson 1975) . This computes a 'total cost' for cancer in the United States in 1962 of $11.2 billion. Within this total, drugs cost 0.3%, or $30.8 million. However, in many ways the total of $1 1.2 billion is a fallacious figure. Almost 90% of it is made up of 'indirect' costslosses due to work missed through sickness absence and, predominantly, the notional value to be placed on lives lost. This paper does not discuss the conceptual difficulties in producing meaningful 'indirect' costs of sickness on this basis. However, because of the fallacies which can arise from the use of notional 'indirect' costs, it will concentrate exclusively on the direct costs. That is the money actually spent on cancer therapy and research.
For 1962, these direct costs in the USA amounted to $1.2 billion, and of this subtotal the drug bill accounted for 2.5%. Many of the drugs would no doubt have been steroids and analgesics. It is estimated that the expenditure on specific anticancer drugs in the USA was still only about $70 million by 1977, although in that country their usage has been increasing at a rate of more than 30% per year. It is, of course, this fast rate of growth in expenditure on cancer chemotherapy which gives rise to the misplaced economic concern. By 1980, it is estimated that worldwide sales I Based on paper read to Section of Oncology, 25 January 1978 0141-0768/78/0071-0633/$01-00/0 of anticancer agents will have reached $1000 million (Scrip 1977) . But it must be remembered that this is still less than the USA alone had been spending on all forms of cancer therapy by 1962. Apart from the USA, Japan probably has the fastest growth in the use of cancer chemotherapy. There is practically no hard information on the costs of cancer chemotherapy itself in Britain. In 1975, the cost of prescriptions written by general practitioners amounted to less than £0.5 million. However, the vast majority of cancer drugs would have been used in hospitals, so this figure gives no indication of total usage. Nevertheless, it is probably still true that expenditure on cancer therapy is a very small proportion of the total costs of cancer under the NHS.
The only other hard statistics which are available are the figures relating to the amount spent on pharmaceutical research in the cancer field in the United States. For 1974, the pharmaceutical industry there spent a total of $932 million on research and development. Of this total, 14% was devoted to cancer; that is $130 million. This must be compared to estimated total sales of anticancer agents in the USA of only $70 million; clearly the pharmaceutical industry is investing in cancer out of current profits on other types of medicines. They can only do this in the hope of eventually recovering their research and development investment from new products for cancer itself. But there are signs that the industry-may be losing confidence in the possibility of ever recouping its investment in the cancer field. Between 1973 and 1974 Manufacturers' Association 1976). Amongst the different therapeutic categories competing for limited research and development funds, cancer fell from third place to fourth. Cardiovascular preparations had joined those for the central nervous system and the anti-infectives in attracting a larger proportion of research and development funds than cancer. The most likely explanation relates to the misconceptions about the costs and economics of cancer therapy. It now seems that cancer chemotherapy is generally regarded as an extremely expensive gameand, indeed, is now sometimes seen as being prohibitively expensive. Some patients may now not be receiving particular anticancer agents simply because the consultant considers them to be too expensive.
This creates an almost entirely novel situation. It has been a characteristic of the past thirty years under the NHS that many treatments have had to be 'rationed', usually by the development of long hospital waiting lists. However, chemotherapy has been almost entirely free of this rationing process. Because medicines are relatively inexpensive and have never accounted for more than about 10% of the total NHS bill, they have always been freely prescribable. A course of antibiotics or tranquillizers costing a pound or so could be provided whenever it was deemed necessary. By contrast, surgical or radiological procedures costing hundreds of pounds could be made available only in limited supply. Now, for cancer chemotherapy, the price of medicines is sometimes comparable to the cost of radiotherapy or surgery. However, to put this situation into perspective, it is important to understand two factors.
First, it is extremely difficult to make fair comparisons between the cost of chemotherapy and alternative treatments. The cost of prescribed medicines appears as a direct charge in a limited hospital budget. By contrast, the costs of surgery and radiotherapy appear only indirectly in the accounts. The aggregate of all surgical costsdoctors' and nurses' time, hospital maintenance, 'hotel costs' and such likeare spread over many different budget headings, so that it is difficult to compute the average cost for an operation. For radiotherapy, the initial capital cost of the equipment is an important item which has to be spread over many individual treatments.
Put in economic terms, the marginal cost of one extra operation or one extra dose of radiotherapy is very small; but the average cost of such treatments is extremely high. By contrast, for chemotherapy the marginal cost to the hospital of each extra dose is exactly equal to the average cost of all. And unfortunately in short-term hospital budgetingin attempting to keep within specific cash limitsit is usually the marginal cost rather than the average cost which is taken into account. Hence chemotherapy appears disproportionately expensive, whereas in reality it will often be very much cheaper for the NHS than surgery or radiotherapy.
Secondly, it is easy to confuse research costs with the cost of routine inservice treatment. In the treatment of many cancers, all forms of treatment should properly be regarded as research. The costs of such treatment should therefore be regarded as research costs. As such, it will always be expensive, like any form of modem research.
In practical terms, the price of a 'research drug' cannot be compared with the cost of routine therapy. With the former, the manufacturer's investment in research must be recovered from very small volume sales; hence each individual dose must be disproportionately expensive. It is only when a medicine has been proved to be of value in routine therapy that a larger volume of usage will enable prices to be reduced. Once again using economic terms, the marginal cost of producing extra tablets is trivial; it is the very high cost of their original development which makes new medicines expensive. This allows prices to be sharply reduced as their volume of sales increases. Hence in the economics of cancer chemotherapy there appears to be a chicken and egg situation. If new treatments are considered to be 'too expensive', and consequently are not used, their value can never be demonstrated. In turn, they will never come into routine use and their price never will be able to be reduced. Very high initial research costs should be accepted as a price of eventual progress.
Ironically, there is an economic paradox in this situation. Whereas extra surgery or radiotherapy on a local short-term scale appears cheap, any long-term increase in these activities will involve substantial extra costs for the provision of extra facilities and staff. On this time-scale, the average costs of additional surgery or radiotherapy will match the high average cost of present activities. By contrast, an increase in the use of chemotherapy will, in the long-term, involve the NHS in only marginal cost increases. The high cost of research will already have been largely recovered. Thus, in the long-term the average cost of chemotherapy falls as usage increases whereas that of surgery and radiotherapy will remain constant. This is the reverse of the position as it appears to an Area Finance Officer on a day-to-day basis.
It seems clear from the American research and development figures that there is a real danger that research in chemotherapy may be being hindered by a failure to understand this situation. Because the cost of chemotherapy is judged on an inappropriate economic basis, it may be at a disad-vantage in relation to surgery and radiotherapy. Both in relation to its effectiveness and in relation to its cost, chemotherapy should be assessed on an equal footing with alternative treatments, taking long-term economic factors into account.
In summary, therefore, the total cost of chemotherapy often appears disproportionately expensive in the short-term because, unlike surgery or radiotherapy, the marginal cost of each extra dose prescribed is exactly equal to the average cost of all treatments. It is only once large-scale use of effective chemotherapeutic agents has become justified on clinical grounds that their prices will be able to fall to match the relatively low price of other medicines. In the meantime, their high price should be considered as a research cost. Perhaps because this situation has been misunderstood, there is some evidence that the pharmaceutical industry may be retrenching its position in relation to cancer chemotherapy, which must be to the long-term disadvantage of cancer patients.
G Teeling-Smith 
Hypertension in childhood'
Many adults with hypertension remain undetected or inadequately treated. The proportion of children with hypertension who are undetected or inadequately treated is probably even higher. The reasons for this are several and include the fact that hypertension is less common in children, and therefore tends to be forgotten. Furthermore, the measurement of a child's blood pressure is often awkward and sometimes difficult, and when the blood pressure has been measured there may be problems in deciding upon its normality and the criteria for hypertension. Blood pressure increases up to the age of 15 when adult levels are reached ( Table 1 ). The mean blood pressure for a six-month-old is 80/45 and rises to 97/65 at five years and 110/70 at ten years. If one accepts the upper level of normal as being around the 95th percentile, then it is clear that a blood pressure of 130/90 in a five-year-old would be grossly abnormal and, if of sudden onset, it could cause major complications for the child. In general, those children who have a blood pressure about the 90th percentile in early life, tend to remain at that end of the distribution curve in later childhood. Recent work suggests that the blood pressure in the neonatal period is a predictor of blood pressure in later childhood and probably adult life also (Shinebourne et al. 1977 , Buck 1973 . The blood pressure of any child has a close correlation with that of the parents and siblings (Miall et al. 1967 , Zinner et al. 1971 ). In childhood, there is no sex difference in blood pressure levels.
The blood pressure of children may, at best, be awkward to measure and, at worst, very difficult. Whether measured by palpation, auscultation or the flush method, considerable patience and skill are required. It is a job for a trained person, and should not be delegated to a trainee nurse. The child needs to be quiet and at ease. A struggling, terrified child will yield a high blood pressure. The sphygmomanometer cuff must be chosen with care: too small a cuff yields a false high reading.
The cuff width should be two-thirds the distance between the tip of the shoulder and tip of the elbow. In practice, it is best to use the largest cuff that will fit on the upper arm and yet still allow room for a stethoscope over the brachial artery in the ante-cubital fossa. Many of the smaller paediatric cuffs which are necessary for young children are not only narrow but short also. With these cuffs it is imperative to ensure that the rubber bladder lies over the artery which it is to occlude. The best sphygmomanometer cuffs are those containing bladders which, regardless of width, are long and completely encircle the arm.
Auscultation is the method of choice; this may be difficult in the very young. The Doppler machine for the amplification of blood-flow sounds is a useful aid in any paediatric unit, and enables the
